High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow
Open Access
- 6 April 2011
- journal article
- research article
- Published by Springer Nature in Cellular Oncology
- Vol. 34 (4) , 289-296
Abstract
Background Acute Myeloid Leukemia (AML) bone marrow biopsies at diagnosis display enhanced angiogenesis and increased VEGFA expression. In a xenograft mouse model it was described that availability of free VEGFA versus bound VEGFA is related to different vascular morphology. In this study we investigate the relationship between vascular morphology within AML bone marrow biopsies and AML derived VEGFA levels. Methods Vessel count and surface area (Chalkley count) were calculated in AML bone marrow biopsies at diagnosis (n = 32), at remission (n = 8) and Normal Bone Marrow (n = 32) using immunohistochemical staining for FVIII, CD31, CTIV, SMA and VEGFA. VEGFA protein levels were measured. Results High vessel count was associated with an immature vessel status. Combining vessel count and Chalkley count different vessel morphology patterns were quantified within AML bone marrow biopsies. Three different subgroups could be distinguished. The subgroup (37.5% of the samples) exhibiting a high vessel count and vessels with predominantly large lumen (normal Chalkley count) was associated with high secreted VEGFA protein levels. Conclusion Different vasculature patterns are seen in AML bone marrow biopsies, defined by combining number and size of vessel. These quantified morphology patterns, combined with VEGFA levels, might be of value in the success of VEGF/VEGFR-signaling interference approaches.Keywords
This publication has 28 references indexed in Scilit:
- Tumour vasculature and angiogenic profile of paediatric pilocytic astrocytoma; is it much different from glioblastoma?Neuropathology and Applied Neurobiology, 2010
- Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemiaHaematologica, 2010
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanomaJournal of Experimental Medicine, 2010
- Where is VEGF in the body? A meta-analysis of VEGF distribution in cancerBritish Journal of Cancer, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous LeukemiasClinical Cancer Research, 2004
- A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemiaBlood, 2003
- Angiogenesis and apoptosisSeminars in Cancer Biology, 2003
- Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)Blood, 2002
- Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumoursEuropean Journal of Cancer, 2002